Meeting
2022 ASCO Annual Meeting
Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.
Authors
Natasha Hunter
University of Washington, Seattle, WA
Natasha Hunter , Lanell Peterson , David A. Mankoff , Mark Muzi , Delphine L. Chen , Shaveta Vinayak , William R Gwin III, Jennifer M. Specht , Hannah M. Linden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1042)
DOI
10.1200/JCO.2022.40.16_suppl.1042
Abstract #
1042
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman
Poster
2022 ASCO Annual Meeting
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER⁺) breast cancer or advanced solid tumors.
First Author: Kevin Kalinsky
Poster
2022 ASCO Annual Meeting
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
First Author: Komal L. Jhaveri